{
    "id": "623a24d6f0baec9a1b000002",
    "question": "Is telomestatin, a novel statin drug used to treat high cholesterol?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to look for any information about a drug called 'telomestatin' in the provided documents. After reviewing the documents, we can see that none of them mention a drug called 'telomestatin'. The documents do, however, mention statins, which are a class of drugs that include atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, rosuvastatin, and pitavastatin. Statins are used to lower cholesterol levels and are available as generic medications. Given that there is no mention of a drug called 'telomestatin' in the provided documents, it can be concluded that telomestatin is not a statin drug used to treat high cholesterol.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_28266",
            "title": "InternalMed_Harrison",
            "content": "Statins are well tolerated and can be taken in tablet form once a day. Potential side effects include dyspepsia, headaches, fatigue, and muscle or joint pains. Severe myopathy and even rhabdomyolysis occur rarely with statin treatment. The risk of statin-associated myopathy is increased by the presence of older age, frailty, renal insufficiency, and coadministration of drugs that interfere with the metabolism of statins, such as erythromycin and related antibiotics, antifungal agents, immunosuppressive drugs, and fibric acid deriva- Disorders of Lipoprotein Metabolism Abbreviations: GI, gastrointestinal; HDL-C, high-density lipoprotein cholesterol; HoFH, homozygous familial hypercholesterolemia; LDL, low-density lipoprotein; LDL-C, LDL-cholesterol; LPL, lipoprotein lipase; TG, triglyceride; VLDL, very-low-density lipoprotein."
        },
        {
            "id": "InternalMed_Harrison_19003",
            "title": "InternalMed_Harrison",
            "content": "The 2013 cholesterol guideline focused on 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) rather than other classes of lipid-modulating drugs, including fibric acid derivatives, cholesterol absorption inhibitors such as ezetimibe, and niacin products. The guideline cites the lack of contemporary randomized clinical trial evidence that supports the efficacy of these nonstatin lipid-modifying agents in cardiovascular event reduction. The cholesterol guideline defined four statin benefit groups (Table 291e-2): (1) all individuals who have clinical atherosclerotic cardiovascular disease (ASCVD), therefore considered \u201csecondary prevention\u201d; (2) those with LDL cholesterol \u2265190 mg/dL without a secondary cause such as a high intake of saturated or trans fats, various drugs, or certain diseases; (3) individuals with diabetes without established cardiovascular disease who are 40\u201375 years old and have LDL cholesterol of 70\u2013189 mg/dL; and (4) those without"
        },
        {
            "id": "Pharmacology_Katzung_3935",
            "title": "Pharmacology_Katzung",
            "content": "Boekholdt SM et al: Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-analysis. Circulation 2013;128:1504. Bonow RO, Yancy CW: High-intensity statins for secondary prevention. JAMA Cardiol 2017;2:55. Cannon CP et al: Ezetimibe added to statin therapy after acute coronary syndrome. N Engl J Med 2015;372:2387. Chou R et al: Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;316:2008. Dron JS, Hegele RA: Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. Curr Opin Lipidol 2017;28:161. Elam M, Lovato E, Ginsberg H: The role of fibrates in cardiovascular disease prevention, The ACCORD\u2013lipid perspective. Curr Opin Lipidol 2011;22:55."
        },
        {
            "id": "InternalMed_Harrison_19017",
            "title": "InternalMed_Harrison",
            "content": "CHAPTER 291e The Pathogenesis, Prevention, and Treatment of Atherosclerosis Moderate-to-high intensity statin \u02dc7.5% estimated 10-y ASCVD risk and age 40\u201375 y ASCVD prevention benefit of statin therapy may be less clear in other groups In selected individuals, consider additional factors influencing ASCVD risk and potential ASCVD risk benefits and adverse effects, drug\u2013drug interactions, and patient preferences for statin treatment FIGuRE 291e-4 Major recommendations for statin therapy for atherosclerotic cardiovascular disease (ASCVD) prevention. LDL-C, low-density lipoprotein cholesterol. (From NJ Stone et al: J Am Coll Cardiol, 2013, doi: 10.1016/j.jacc.2013.11.002.)"
        },
        {
            "id": "InternalMed_Harrison_28264",
            "title": "InternalMed_Harrison",
            "content": "HmG-coa reductaSe inHiBitorS (StatinS) Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. By inhibiting cholesterol biosynthesis, statins lead to increased hepatic LDL receptor activity and accelerated clearance of circulating LDL, resulting in a dose-dependent reduction in plasma levels of LDL-C. The magnitude of LDL lowering associated with statin treatment varies widely among individuals, but once a patient is on a statin, the doubling of the statin dose produces an ~6% further reduction in the level of plasma LDL-C. The statins currently available differ in their LDL-C\u2013reducing potency (Table 421-5). Currently, there is no convincing evidence that any of the different statins confer an advantage that is independent of the effect on LDL-C. Statins also reduce plasma TGs in a dose-dependent fashion, which is roughly proportional to their LDL-C\u2013lowering effects (if the TGs are <400 mg/dL). Statins have a modest HDL-raising effect (5\u201310%) that is not"
        },
        {
            "id": "InternalMed_Harrison_28313",
            "title": "InternalMed_Harrison",
            "content": "LDL CHOLESTEROL (SEE ALSO CHAP. 421) The rationale for the NCEP:ATPIII\u2019s development of criteria for the metabolic syndrome was to go beyond LDL cholesterol in identifying and reducing the risk of CVD. The working assumption by the panel was that LDL cholesterol goals had already been achieved and that increasing evidence supports a linear reduction in CVD events as a result of progressive lowering of LDL cholesterol with statins. For patients with the metabolic syndrome and diabetes, a statin should be prescribed. For those patients with diabetes and known CVD, the current evidence supports a maximum of penultimate dose of a potent statin (e.g., atorvastatin or rosuvastatin). For those patients with the metabolic syndrome but without diabetes, a score that predicts a 10-year CVD risk exceeding 7.5% should also take a statin. With a 10-year risk of <7.5%, use of statin therapy is not evidence based."
        },
        {
            "id": "Pharmacology_Katzung_3925",
            "title": "Pharmacology_Katzung",
            "content": "who have familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional reduction of LDL. They are given with diet and maximal tolerated statin and/or ezetimibe. Development of small molecules and antisense oligonucleotides to inhibit PCSK9 is underway. Studies of PCSK9 inhibition should be approached with caution because of its established role in normal cell biology. These agents are very expensive."
        },
        {
            "id": "Pharmacology_Katzung_3849",
            "title": "Pharmacology_Katzung",
            "content": "A 42-year-old woman has heterozygous familial hyper-cholesterolemia (HeFH) but is otherwise well and has no symptoms of coronary or peripheral vascular disease. A carotid ultrasound was normal. Her mother had a myo-cardial infarction at age 51 and had no known risk factors other than her presumed HeFH. The patient also has ele-vated lipoprotein (a) at 2.5 times normal and low HDL-C (43 mg/dL). She developed muscle symptoms with each of 3 statins (atorvastatin, rosuvastatin, and simvastatin) so they were discontinued although she did not develop elevated levels of creatine kinase. Her untreated LDL-C is 235 mg/dL and triglycerides 125 mg/dL. Her LDL-C goal for primary prevention of arteriosclerotic vascular disease is in the 70-mg/dL range because of her multiple lipopro-tein risk factors and her mother\u2019s history of premature coronary artery disease. She has no other risk factors and her diet and exercise habits are excellent. How would you manage this patient?"
        },
        {
            "id": "InternalMed_Harrison_19006",
            "title": "InternalMed_Harrison",
            "content": "The 2013 guideline focus on statins reflects an extensive body of rigorous evidence that supports the effectiveness of this class of drugs PART 10 Disorders of the Cardiovascular System Low HDL cholesterola (<1.0 mmol/L [<40 mg/dL]) Family history of premature CHD aHDL cholesterol \u22651.6 mmol/L (\u226560 mg/dL) has been viewed as a \u201cnegative\u201d risk factor. Abbreviations: BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein. in cardiovascular event reduction and an acceptable risk-benefit relationship (Fig. 291e-5). Moreover, because almost all statins are now available as generic statins medications, cost has become much less of an impediment to their use."
        },
        {
            "id": "InternalMed_Harrison_28320",
            "title": "InternalMed_Harrison",
            "content": "HDL CHOLESTEROL (SEE ALSO CHAP. 421) Very few lipid-modifying compounds increase HDL cholesterol levels. Statins, fibrates, and bile acid sequestrants have modest effects (5\u201310%), whereas ezetimibe and omega-3 fatty acids have no effect. Nicotinic acid is the only currently available drug with predictable HDL cholesterol-raising properties. The response is dose related, and nicotinic acid can increase HDL cholesterol by ~30% above baseline. After several trials of nicotinic acid versus placebo in statin-treated patients, there is still no evidence that raising HDL with nicotinic acid beneficially affects CVD events in patients with or without the metabolic syndrome. BLOOD PRESSURE (SEE ALSO CHAP. 298) The direct relationship between blood pressure and all-cause mortality rate has been well established in studies comparing patients"
        },
        {
            "id": "Pharmacology_Katzung_3893",
            "title": "Pharmacology_Katzung",
            "content": "Because cholesterol synthesis occurs predominantly at night, reductase inhibitors\u2014except atorvastatin, rosuvastatin, and pitavastatin\u2014should be given in the evening. Absorption generally (with the exception of pravastatin and pitavastatin) is enhanced by food. Daily doses of lovastatin vary from 10 to 80 mg. Pravastatin is nearly as potent on a mass basis as lovastatin with a maximum recommended daily dose of 80 mg. Simvastatin is twice as potent and is given in doses of 5\u201380 mg daily. Because of increased risk of myopathy with the 80-mg/d dose, the U.S. Food and Drug Administration (FDA) issued labeling for scaled dosing of simvastatin and combined ezetimibe/simvastatin in 2011. Pitavastatin is given in doses of 1\u20134 mg daily. Fluvastatin appears to be about half as potent as lovastatin on a mass basis and is given in doses of 10\u201380 mg daily. Atorvastatin is given in doses of 10\u201380 mg/d, and rosuvastatin at 5\u201340 mg/d. The dose-response curves of pravastatin and especially of"
        },
        {
            "id": "InternalMed_Harrison_19007",
            "title": "InternalMed_Harrison",
            "content": "The clinical use of effective pharmacologic strategies for lowering LDL has reduced cardiovascular events markedly, but a considerable burden of residual risk remains even in patients treated with high-intensity statins. Hence, current studies are evaluating other avenues to address the residual burden of cardiovascular disease that persists despite statin treatment. Inhibitors of genetic studies identified proprotein convertase subtilisin kexin-like 9 (PCSK9) as a regulator of LDL levels associated with cardiovascular outcomes. Interaction of the LDL receptor with PCSK9 hastens the receptor\u2019s degradation, and hence yields higher circulating LDL concentrations. Genetic variants that lower PCSK9 activity appear to protect against cardiovascular events. Monoclonal antibodies that neutralize PCSK9 lower LDL levels even in statin-treated patients and are currently under investigation as novel therapeutics to lower cardiovascular risk."
        },
        {
            "id": "Pharmacology_Katzung_3937",
            "title": "Pharmacology_Katzung",
            "content": "LaRosa JC et al: Safety and effect of very low levels of low density lipoprotein cholesterol on cardiovascular events. Am J Cardiol 2013;111:1221. Mampuya WM et al: Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J 2013;166:597. Nduka C et al: Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis. Int J Cardiol 2015;199:307. Perry CM: Lomitapide: A review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs 2013;13:265. Raal FJ, Stein EA: The effects of mipomersen on inhibiting hepatic VLDL apolipoprotein B 100 and propensity for hepatic steatosis. Clin Chem 2016;62:1052. Reith C, Armitage J: Management of residual risk after statin therapy. Atherosclerosis 2016;245;161. Rodriguez F: Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2016;2:47."
        },
        {
            "id": "InternalMed_Harrison_19016",
            "title": "InternalMed_Harrison",
            "content": "Heart-healthy lifestyle habits are the foundation of ASCVD prevention. In individuals not receiving cholesterol-lowering drug therapy, recalculate estimated 10-y ASCVD risk every 4\u20136 y in individuals aged 40-75 y without clinical ASCVD or diabetes and with LDL\u2013C 70-189 mg/dL. Age >75 y OR if not candidate for high-intensity statin Moderate-intensity statin High-intensity statin (Moderate-intensity statin if not candidate for high-intensity statin) Moderate-intensity statin Estimated 10-y ASCVD risk \u02dc7.5% High-intensity statin Estimate 10-y ASCVD risk with pooled cohort equations Clinical ASCVD LDL\u2013C \u02dc190 mg/dL Diabetes Type 1 or 2 age 40\u201375 y Yes Yes Yes Yes Age \u00b075 y High-intensity statin (Moderate-intensity statin if not candidate for high-intensity statin) No No No Yes CHAPTER 291e The Pathogenesis, Prevention, and Treatment of Atherosclerosis Moderate-to-high intensity statin \u02dc7.5% estimated 10-y ASCVD risk and age 40\u201375 y"
        },
        {
            "id": "Cell_Biology_Alberts_3645",
            "title": "Cell_Biology_Alberts",
            "content": "This regulated pathway for cholesterol uptake is disrupted in individuals who inherit defective genes encoding LDL receptors. The resulting high levels of blood cholesterol predispose these individuals to develop atherosclerosis prematurely, and many would die at an early age of heart attacks resulting from coronary artery disease if they were not treated with drugs such as statins that lower the level of blood cholesterol. In some cases, the receptor is lacking altogether. In others, the receptors are defective\u2014in either the extracellular binding site for LDL or the Figure 13\u201350 Schematic representation of macropinocytosis. cell signaling events lead to a reprogramming of actin dynamics, which in turn triggers the formation of cell-surface ruffles. as the ruffles collapse back onto the cell surface, they nonspecifically trap extracellular fluid and macromolecules and particles contained in it, forming large vacuoles, or macropinosomes, as shown."
        },
        {
            "id": "Gynecology_Novak_891",
            "title": "Gynecology_Novak",
            "content": "A) reductase inhibitors (statins) include atorvastatin, \ufb02uvastatin, lovastatin, pravastatin, and simvastatin. These medicines inhibit HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. Several clinical trials showed that pravastatin, simvastatin, and lovastatin have a beneficial effect in cardiovascular disease. Statins are better tolerated than other lipid-lowering drugs, but reported side effects include severe myalgias, muscle weakness with increases in creatine phosphokinase, and, rarely, rhabdomyolysis, leading to renal failure."
        },
        {
            "id": "InternalMed_Harrison_28314",
            "title": "InternalMed_Harrison",
            "content": "Diets restricted in saturated fats (<7% of calories) and trans-fats (as few as possible) should be applied aggressively. Although less evidence exists, dietary cholesterol should also be restricted. If LDL cholesterol remains elevated, pharmacologic intervention is needed. Treatment with statins, which lower LDL cholesterol by 15\u201360%, is evidence based and is the first-choice medication intervention. Of note, for each doubling of the statin dose, LDL cholesterol is further lowered by only ~6%. Hepatotoxicity (more than a threefold increase in hepatic aminotransferases) is rare, and myopathy is seen in ~10% of patients. The cholesterol absorption inhibitor ezetimibe is well tolerated and should be the second- choice medication intervention. Ezetimibe typically reduces LDL cholesterol by 15\u201320%. The bile acid sequestrants cholestyramine, colestipol, and colesevalam may be more effective than ezetimibe but, because they can increase triglyceride levels, must be used with caution in"
        },
        {
            "id": "Pharmacology_Katzung_3887",
            "title": "Pharmacology_Katzung",
            "content": "COMPETITIVE INHIBITORS OF HMG-COA REDUCTASE (REDUCTASE INHIBITORS: \u201cSTATINS\u201d) These compounds are structural analogs of HMG-CoA (3-hydroxy3-methylglutaryl-coenzyme A, Figure 35\u20133). Lovastatin, atorvastatin, fluvastatin, pravastatin, simvastatin, rosuvastatin, and pitavastatin belong to this class. They are most effective in reducing LDL. Other effects include decreased oxidative stress and vascular inflammation with increased stability of atherosclerotic lesions. It has become standard practice to initiate reductase inhibitor therapy immediately after acute coronary syndromes, regardless of lipid levels."
        },
        {
            "id": "Pharmacology_Katzung_3930",
            "title": "Pharmacology_Katzung",
            "content": "If the maximum tolerated statin dose fails to achieve the LDL cholesterol goal in a patient with hypercholesterolemia, niacin may be helpful. This combination may be useful in the treatment of familial combined hyperlipoproteinemia. This combination is synergistic in treating primary hypercholesterolemia and may be of use in the treatment of patients with homozygous familial hypercholesterolemia who have some receptor function. Fenofibrate appears to be complementary with most statins in the treatment of familial combined hyperlipoproteinemia and other conditions involving elevations of both LDL and VLDL. The combination of fenofibrate with rosuvastatin appears to be especially well tolerated. Some other statins may interact unfavorably owing to effects on cytochrome P450 metabolism. In any case, particular vigilance for liver and muscle toxicity is indicated. COMBINATIONS OF RESINS, EZETIMIBE, NIACIN, & REDUCTASE INHIBITORS"
        },
        {
            "id": "InternalMed_Harrison_28265",
            "title": "InternalMed_Harrison",
            "content": "reduce plasma TGs in a dose-dependent fashion, which is roughly proportional to their LDL-C\u2013lowering effects (if the TGs are <400 mg/dL). Statins have a modest HDL-raising effect (5\u201310%) that is not generally dose-dependent."
        },
        {
            "id": "Pharmacology_Katzung_4630",
            "title": "Pharmacology_Katzung",
            "content": "serum creatinine 0.86 mg/dL (0.61\u20131.24), total choles-terol 128 mg/dL, triglycerides 86 mg/dL, HDL cholesterol 38 mg/dL, and LDL cholesterol 73 mg/dL (on atorvastatin 40 mg daily). How would you treat this patient?"
        },
        {
            "id": "Pharmacology_Katzung_3894",
            "title": "Pharmacology_Katzung",
            "content": "on a mass basis and is given in doses of 10\u201380 mg daily. Atorvastatin is given in doses of 10\u201380 mg/d, and rosuvastatin at 5\u201340 mg/d. The dose-response curves of pravastatin and especially of fluvastatin tend to level off in the upper part of the dosage range in patients with moderate to severe hypercholesterolemia. Those of other statins are somewhat more linear."
        },
        {
            "id": "InternalMed_Harrison_28270",
            "title": "InternalMed_Harrison",
            "content": "inhibitor that mandate discontinuing the medication. Severe clinical hepatitis binds directly to and inhibits NPC1L1 and blocks the intestinal associated with statins is exceedingly rare, and the trend is toward absorption of cholesterol. Ezetimibe (10 mg) inhibits cholesterol absorption by almost 60%, resulting in a reduction in delivery of dietary sterols in the liver and an increase in hepatic LDL receptor expression. The mean reduction in plasma LDL-C on ezetimibe (10 mg) is 18%, and the effect is additive when used in combination with a statin. Effects on TG and HDL-C levels are negligible. When used in combination with a statin, monitoring of liver transaminases is recommended. The only roles for ezetimibe in monotherapy are in patients who do not tolerate statins and in sitosterolemia."
        },
        {
            "id": "InternalMed_Harrison_28318",
            "title": "InternalMed_Harrison",
            "content": "Endocrinology and Metabolism Health and Disease F. Richard Bringhurst, Marie B. Demay, Stephen M. Krane, Henry M. Kronenberg BONE STRUCTURE AND METABOLISM 423 SEC Tion 4 2454 clear evidence that fibrates reduce CVD risk; however, post hoc analyses of several studies demonstrated that patients with baseline triglyceride levels >200 mg/dL and HDL cholesterol levels <35 mg/ dL did benefit. Other drugs that lower triglyceride levels include statins, nicotinic acid, and\u2014in high doses\u2014omega-3 fatty acids. For this purpose, an intermediate or high dose of the \u201cmore potent\u201d statins (atorvastatin, rosuvastatin) is needed. The effect of nicotinic acid on fasting triglycerides is dose related and ~20\u201335%, an effect that is less pronounced than that of fibrates. In patients with the metabolic syndrome and diabetes, nicotinic acid may increase fasting glucose levels. Omega-3 fatty acid preparations that include high doses of docosahexaenoic acid plus eicosapentaenoic acid (~1.5\u20134.5 g/d) or"
        },
        {
            "id": "InternalMed_Harrison_19022",
            "title": "InternalMed_Harrison",
            "content": "PART 10 Disorders of the Cardiovascular System FIGuRE 291e-5 The Cholesterol Treatment Trialists Collaboration meta-analyzed 27 randomized clinical trials evaluating statin therapy. They found profound decreases in both major vascular events and vascular death (not shown) proportional to the magnitude of low-density lipoprotein (LDL) cholesterol reduction achieved with statin treatment. This diagram shows the results of this meta-analysis for vascular death. (From Lancet 380:581, 2012.) and Estrogen/Progestin Replacement Study (HERS), postmenopausal female survivors of acute MI were randomized to an estrogen/progestin combination or to placebo. This study showed no overall reduction in recurrent coronary events in the active treatment arm. Indeed, early in the 5-year course of this trial, a trend occurred toward an increase"
        },
        {
            "id": "InternalMed_Harrison_28317",
            "title": "InternalMed_Harrison",
            "content": "A fibrate (gemfibrozil or fenofibrate) is the drug of choice to lower fasting triglyceride levels, which are typically reduced by 30\u201345%. Concomitant administration with drugs metabolized by the 3A4 cytochrome P450 system (including some statins) increases the risk of myopathy. In these cases, fenofibrate may be preferable to gemfibrozil. In the Veterans Affairs HDL Intervention Trial, gemfibrozil was administered to men with known CHD and levels of HDL cholesterol <40 mg/dL. A coronary disease event and mortality rate benefit was experienced predominantly among men with hyperinsulinemia and/or diabetes, many of whom were identified retrospectively as having the metabolic syndrome. Of note, the degree of triglyceride lowering in this trial did not predict benefit. Although levels of LDL cholesterol did not change, a decrease in LDL particle number correlated with benefit. Several additional clinical trials have not shown The Metabolic Syndrome"
        },
        {
            "id": "Biochemistry_Lippincott_774",
            "title": "Biochemistry_Lippinco",
            "content": "Hormonal regulation: The activity of HMG CoA reductase is controlled hormonally. An increase in insulin favors dephosphorylation (activation) of the reductase, whereas an increase in glucagon and epinephrine has the opposite effect. 5. Drug inhibition: The statin drugs (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin) are structural analogs of HMG CoA and are (or are metabolized to) reversible, competitive inhibitors of HMG CoA reductase (Fig. 18.7). They are used to decrease plasma cholesterol levels in patients with hypercholesterolemia. IV. CHOLESTEROL DEGRADATION"
        },
        {
            "id": "Biochemistry_Lippincott_1264",
            "title": "Biochemistry_Lippinco",
            "content": "2. Benefits of lowering plasma cholesterol: Dietary or drug treatment of hypercholesterolemia has been shown to be effective in decreasing LDLC, increasing HDL-C, and reducing the risk for cardiovascular events. The diet-induced changes in plasma cholesterol concentrations are modest, typically 10%\u201320%, whereas treatment with statin drugs decreases plasma cholesterol by 30%\u201360% (see p. 224). [Note: Dietary and drug treatment can also lower TAG.] B. Dietary fats and plasma lipids TAG are quantitatively the most important class of dietary fats. The influence of TAG on blood lipids is determined by the chemical nature of their constituent fatty acids. The absence or presence and number of double bonds (saturated versus mono-and polyunsaturated), the location of the double bonds (\u03c9-6 versus \u03c9-3), and the cis versus trans configuration of the unsaturated fatty acids are the most important structural features that influence blood lipids."
        },
        {
            "id": "InternalMed_Harrison_29959",
            "title": "InternalMed_Harrison",
            "content": "Several trials have confirmed that statin drugs reduce the risk of 2569 stroke even in patients without elevated LDL or low HDL. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed benefit in secondary stroke reduction for patients with recent stroke or TIA who were prescribed atorvastatin, 80 mg/d. The primary prevention trial, Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), found that patients with low LDL (<130 mg/dL) caused by elevated C-reactive protein benefitted by daily use of this statin. Primary stroke occurrence was reduced by 51% (hazard ratio 0.49, p = .004), and there was no increase in the rates of intracranial hemorrhage. Meta-analysis has also supported a primary treatment effect for statins given acutely for ischemic stroke. Therefore, a statin should be considered in all patients with prior ischemic stroke. Tobacco smoking should be discouraged in all patients (Chap."
        },
        {
            "id": "Pathology_Robbins_1523",
            "title": "Pathology_Robbins",
            "content": "In recent years, a new mechanism of posttranslational regulation of plasma LDL levels has been elucidated, wherein an enzyme referred to as PCSK9 causes intracellular degradation of LDL receptors in hepatocytes, before they reach the cell surface. With fewer LDL receptors on the cell surface, there is reduced uptake of plasma LDL, leading to hypercholesterolemia. Families with activating mutations of the gene PCSK9, which codes for the enzyme, have many features similar to classic familial hypercholesterolemia. The discovery of the critical role of LDL receptors in cholesterol homeostasis has led to the rational design of the statin family of drugs that are now widely used to lower plasma cholesterol. They inhibit the activity of HMG-CoA reductase and thus promote greater synthesis of LDL receptors ("
        },
        {
            "id": "InternalMed_Harrison_28269",
            "title": "InternalMed_Harrison",
            "content": "Another consequence of statin therapy can be elevation in widely used class of lipid-lowering drugs. liver transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]). They should be checked before starting cHoleSterol aBSorption inHiBitorS Cholesterol within the lumen therapy, at 2\u20133 months, and then annually. Substantial (greater than of the small intestine is derived from the diet (about one-third) three times the upper limit of normal) elevation in transaminases is and the bile (about two-thirds) and is actively absorbed by the relatively rare, and mild-to-moderate (one to three times normal) enterocyte through a process that involves the protein NPC1L1. elevation in transaminases in the absence of symptoms need not Ezetimibe (Table 421-5) is a cholesterol absorption inhibitor that mandate discontinuing the medication. Severe clinical hepatitis binds directly to and inhibits NPC1L1 and blocks the intestinal associated with statins is exceedingly rare, and"
        },
        {
            "id": "InternalMed_Harrison_27911",
            "title": "InternalMed_Harrison",
            "content": "Rosiglitazone raises low-density lipoprotein (LDL), high-density 2415 lipoprotein (HDL), and triglycerides slightly. Pioglitazone raises HDL to a greater degree and LDL a lesser degree but lowers triglycerides. The clinical significance of the lipid changes with these agents is not known and may be difficult to ascertain because most patients with type 2 DM are also treated with a statin."
        }
    ],
    "scores": [
        0.030361617461251572,
        0.02786747414670568,
        0.027044276027124052,
        0.026785714285714288,
        0.026191883172461104,
        0.025432161012098317,
        0.025086776706916288,
        0.025078628642143202,
        0.024658747165141028,
        0.02440104631115867,
        0.023987733250168928,
        0.023552098406813108,
        0.02344028520499109,
        0.02317036319723031,
        0.022976338996711726,
        0.022676466970996983,
        0.022478529013231312,
        0.02239305374669101,
        0.02228927511075174,
        0.02203573264141246,
        0.02201193755474621,
        0.021772068511198946,
        0.021102859581732823,
        0.020944706029196576,
        0.02092750126968004,
        0.020794893299785667,
        0.02077247888723299,
        0.020658727390502767,
        0.020573966263621436,
        0.020271167681239627,
        0.019938357539435708,
        0.019797008547008547
    ]
}